Echovirus Type 7 Virus-Associated Hemophagocytic Syndrome in a Neonate Successfully Treated With Intravenous Immunoglobulin Therapy: A Case Report

Yuka Watanabe; Takahiro Sugiura; Mari Sugimoto; Yasuko Togawa; Masanori Kouwaki; Norihisa Koyama; Shinji Saitoh

doi:10.3389/fped.2019.00469

Echovirus Type 7 Virus-Associated Hemophagocytic Syndrome in a Neonate Successfully Treated With Intravenous Immunoglobulin Therapy: A Case Report

Front Pediatr. 2019 Nov 14:7:469. doi: 10.3389/fped.2019.00469. eCollection 2019.

Authors

Yuka Watanabe¹, Takahiro Sugiura¹, Mari Sugimoto¹, Yasuko Togawa¹, Masanori Kouwaki¹, Norihisa Koyama¹, Shinji Saitoh²

Affiliations

¹ Department of Pediatrics, Toyohashi Municipal Hospital, Toyohashi, Japan.
² Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Abstract

Virus-associated hemophagocytic syndrome (VAHS) in the neonatal period has a high mortality. Although clear diagnostic criteria and treatment methods have not been established, early diagnosis and treatment are critical. However, treatments for VAHS have potentially serious side effects, especially during the neonatal period. Echovirus type 7 can cause maternal infection around parturition and be vertically transmitted to the neonate and induce VAHS. Intravenous immunoglobulin (IVIG) therapy could be a first-line therapy for neonatal VAHS, so that treatments with potentially serious side effects, including cyclosporine A and etoposide, could be avoided. A case of VAHS associated with echovirus type 7 that was successfully treated with IVIG therapy is reported.

Keywords: echovirus infections; hemophagocytic lymphohistiocytosis; intravenous immunoglobulin therapy; newborn; vertical transmission.

Publication types

Case Reports